Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- peginterferon alfa-2a
- Udenyca (pegfilgrastim)
Interactions between your drugs
pegfilgrastim peginterferon alfa-2a
Applies to: Udenyca (pegfilgrastim), peginterferon alfa-2a
ADJUST DOSING INTERVAL: The safety and efficacy of recombinant human granulocyte colony-stimulating factors (rhG-CSF) administered simultaneously with cytotoxic agents, including cancer chemotherapy, have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.
MANAGEMENT: The prescribing information for pegfilgrastim, eflapegrastim, and efbemalenograstim alfa recommends that these products not be administered between 14 days before and 24 hours after antineoplastic agents.
References (3)
- (2002) "Product Information. Neulasta (pegfilgrastim)." Amgen
- (2022) "Product Information. Rolvedon (eflapegrastim)." Spectrum Pharmaceuticals Inc, 2
- (2023) "Product Information. Ryzneuta Prefilled Syringe (efbemalenograstim alfa)." Evive Biotech
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Epclusa
Epclusa treats chronic hepatitis C in adults and children 3+. This once-daily antiviral combines ...
Mavyret
Mavyret (glecaprevir/pibrentasvir) is an oral combination medicine containing fixed doses of two ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Vemlidy
Vemlidy (tenofovir alafenamide) is an oral, once-daily, antiviral tablet that may be used to treat ...
Harvoni
Harvoni is used to treat hepatitis C virus (HCV) infections in adults and children aged 3 years and ...
Viread
Viread (tenofovir) is used to treat HIV, which causes the acquired immunodeficiency syndrome ...
Baraclude
Baraclude (entecavir) is and antiviral medicine used to treat chronic hepatitis B. Includes ...
Sovaldi
Sovaldi (sofosbuvir) is used to treat chronic hepatitis C virus (HCV) infection. Includes Sovaldi ...
Epivir
Epivir (lamivudine) is used to treat HIV, which causes the acquired immunodeficiency syndrome ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.